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Abstract Studies on the association between micropar-
ticle expressing tissue factor (MP-TF) activity, FVIII
activity (FVIII:C) and recurrent VTE yielded inconclusive
results. We studied these associations in patients diagnosed
with acute pulmonary embolism. Plasma levels of MP-TF
and FVIII activity were measured in 277 patients with a
first and 72 patients with a recurrent VTE. All patients
were categorized based on the quintiles of MP-TF and
FVIII activity in those with a single VTE. For both
markers, odds ratios (ORs) for recurrent VTE were com-
puted using patients in the lowest quintile as a reference
group. No association was observed between MP-TF
activity and recurrent VTE, with an OR of 1.4 (95 % CI
0.7–2.9) in the highest quintile of MP-TF activity. Com-
pared with the reference group, patients in the highest
quintile of FVIII:C were at increased risk of recurrent VTE,
OR 4.2 (95 % CI 1.4–12.2). MP-TF activity was not
associated with recurrent VTE whereas high FVIII:C levels
were associated with a 4-fold increased risk of VTE
recurrence. Future prospective studies are necessary to
explore the potential of FVIII:C as a tool for risk stratifi-
cation, either by itself or in combination with other pro-
thrombotic markers.
Keywords Pulmonary embolism  Recurrent venous
thromboembolism  Micro particle-tissue factor  Factor
VIII activity  Epidemiology
Introduction
Venous thromboembolism (VTE) is the third most common
cardiovascular disease, with an incidence rate of 1–2 per
1000 patient years [1, 2]. After a first event, the 5-years
cumulative risk of recurrent VTE is estimated to be 25 %,
with a case-fatality rate of 11 % [3, 4]. Treatment with anti-
coagulants is highly effective in reducing the risk of recurrent
VTE [5, 6], but this comes at the cost of an increased risk of
major bleeding events [7]. Understanding of the mechanism
of recurrent VTE and identification of patients at high risk of
recurrences are therefore the essential step in determining the
optimal duration of treatment. They requires understanding of
factors contributing to the recurrence of VTE, such as clinical
variables and laboratory markers.
Microparticle expressing tissue factor (MP-TF) has
recently been proposed as a potential key player in the
development of VTE [8]. Tissue factor is the main initiator
of the coagulation cascade and MP-TFs are shed into the
circulation by cells (mainly platelets and to a lower extent
monocytes) during activation or apoptosis. The influence of
MP-TF and MP-TF activity on the occurrence of VTE has
mainly been studied in animal models [9–12]. So far, only
two small clinical studies analyzed the association between
MP-TF or MP-TF activity and the risk of a first or recurrent
VTE [13, 14]. Therefore, the primary aim of our study was
to assess the association between MP-TF activity and the
risk of recurrent VTE.
Additionally, several studies have been performed on
the association between FVIII activity (FVIII:C) (another
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potential key player in the development of VTE) and
recurrent VTE, but they yielded contradictory results
[15–20]. As FVIII:C was measured in our study population
for other purposes, we were also interested in studying the
association between FVIII:C and recurrent VTE.
Methods
We performed a post hoc analysis using data of patients
included in a cohort study that aimed to evaluate the inci-
dence of chronic thromboembolic pulmonary hypertension
(CTEPH) after a diagnosis of acute pulmonary embolism
(PE). Details of this cohort study have been described in
detail previously [21, 22]. In brief, patients diagnosed with
acute PE between 2001 and 2007 in an academic and its
affiliated teaching hospital (i.e. Leiden University Medical
Center, Medical Center Haaglanden, both the Netherlands)
were asked to participate in a CTEPH screening program.
The CTEPH screening program was executed between July
2007 and January 2009. The diagnosis of acute PE was
confirmed by detection of an intraluminal filling defect on
pulmonary angiography or computed tomography pul-
monary angiography, a high probability ventilation perfu-
sion scintigraphy (VQ-scan), or an intermediate probability
VQ-scan in combination with deep vein thrombosis diag-
nosed by ultrasonography. Patients were excluded if they
had known CTEPH or pulmonary hypertension of other
etiology at time of screening, if they were geographic
inaccessible (living outside the Netherlands), if they were
unavailable for objective testing, or recently had undergone
echocardiography ruling out pulmonary hypertension. For
this post hoc analysis, we included all study patients from
the original study cohort except for those without available
lab samples.
All patients were treated for acute PE according to local
clinical practice, with unfractionated heparin or low-
molecular-weight-heparin for at least 5 days after PE
diagnosis followed by a period of at least 6 months of
vitamin K-antagonist treatment.
The protocol of the study was approved by the Institu-
tional review board of the two hospitals and all patients
provided written informed consent.
Screening program
Patients were invited to the vascular medicine outpatient
clinic for a single study visit. This visit was planned at least
1 year after index PE, to rule out the initial effect of acute
PE on the test results (Fig. 1). During the study visit, a
physical examination, echocardiography, pulmonary func-
tion and exercise tests were performed. In addition, blood
samples were drawn. Information on comorbidity,
diagnostic management, previous episodes of VTE, and the
clinical course after index PE was obtained from anamnesis
and medical records.
Outcome
The primary outcome for this post hoc analysis was
recurrent VTE. Follow-up for the endpoint of recurrent
VTE ended at time of index PE (Fig. 1). VTE recurrences
that occurred after the index PE were not taken into
account to limit the effect of potential survival bias on the
association between MP-TF activity or FVIII:C and
recurrent VTE. Recurrent VTE was therefore defined as a
history of VTE at time of index PE. Previous episodes of
superficial DVT or VTE at unusual sites (i.e. retinal vein
occlusion or portal vein thrombosis) were not taken into
account for the diagnosis of recurrent VTE. Medical
records of study patients at both hospitals were searched
for information regarding the diagnosis and treatment of
previous VTE episodes.
Blood sampling
Citrate samples (5 ml) were taken by a single vena punc-
ture. A tourniquet was used prior to sampling, but removed
at time of blood drawing. Citrate samples were centrifuged
for 10 min at 2700 g at 18 C. Samples were stored at
-80 C within 1 h after sampling.
MP-TF activity assay
MP-TF activity was measured in citrate plasma using a TF-
activity assay as described before, with a detection limit of
0.5 fM Xa/min [23]. For the measurement of MP-associated
TF activity (MP-TF activity), MPs were washed extensively
to reduce contamination with plasma proteins (0.5 % in the
final MP preparation); 500 ll of plasma was centrifuged at
18,8909g for 30 min and subsequently, 450 ll was
removed. 900 ll PBS/0.32 % citrate was mixed with the
pellet and the centrifuge step was repeated. Finally, the
pellet was washed with 450 ll of PBS/0.32 % citrate and
Fig. 1 Study design
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resuspended in 70 ll PBS/citrate. MP-TF activity measure-
ments were then performed in triplicates; one sample of the
triplicates functioned as the experimental sample, one
sample as a control by leaving out FVII, and one sample as
another control by adding 125 lg/ml TF blocking antibody.
Twenty-five lM dioleoylphosphatidylserine (DOPS):dio-
leoylphosphatidylcholine (DOPC) (10:90) vesicles were
incubated in a buffer consisting of 10 mm Hepes, pH 7.45,
137 mm NaCl, 4 mm KCl, 5 mg mL-1 ovalbumin, 50 nm
hirudin and 6 mm CaCl2 for 15 min. To 100 lL of this
solution 20 lL MP-suspension was added. 40 lL 5 nm FVII
(or buffer) was added. After 10 min, 25 lL 2.5 mm S2765
was added and the reaction started by adding 40 lL 250 nm
FX. The absorbance at 405 nm (expressed in mAbs) was
recorded for 90 min using a Spectra Thermo Tecan ELISA
reader, and plotted as a function of time (t) and, after cor-
rection for the absorbance in the absence of FVII or presence
of the TF blocking antibody, as a function of t2. The slope of
the latter curve is a measure for the rate of FXa generation
and expressed as mAbs min-2 or as fM FXa min-1.
Factor VIII measurements
Plasma factor VIII activity (FVIII:C) was measured by a
one-stage APTT-based clotting assay using immunode-
pleted FVIII-deficient plasma and automated APTT (Bio-
Merieux, Boxtel, the Netherlands).
Statistical analysis
All patients included in this post hoc analysis were catego-
rized as r cases (i.e. patients diagnosed with recurrent VTE at
time of index PE) or controls (i.e. those with a first VTE at
time of index PE). Mean MP-TF and FVIII activity values
were compared between cases and controls using Mann–
Whitney U-test. Logistic regression analyses were used to
study whether MP-TF en FVIII activity were associated with
recurrent VTE. Patients were categorized based on the
quintiles of MP-TF and FVIII activity levels in controls.
Using patients in the lowest quintile of MP-TF and FVIII
activity as a reference group, odds ratios (ORs) for recurrent
VTE were reported as crude values and as values adjusted for
age, gender, and active malignancy at time of sampling. OR
were not adjusted for VKA use at time of blood sampling as
VKA therapywas not regarded as a confounder in the analysis
on the association between MP-TF or FVIII activity and
recurrent VTE. Sensitivity analyses were performed stratified
for time between index PE and lab sampling, to study its effect
on the association between MP-TF activity, or FVIII:C and
the risk ofVTE recurrences. In addition, we analyzedwhether
patients with FVIII:C[ 1.66 IU/ml (i.e. the cut-off previ-
ously used by Christiansen, et al.) were at increased risk of
recurrent VTE [15].
All analyses were performed using SPSS, version 20
(IBM Corp, Armonk, New York).
Results
Population
We identified 877 patients diagnosed with acute PE
between 2001 and 2007. A total of 11 patients emigrated
and were therefore unavailable for enrollment. Addition-
ally, 259 patients died before 2007 and 19 patients were
already diagnosed with pulmonary hypertension, leaving
588 patients eligible for inclusion (Fig. 1). Of those, 186
were excluded because they were either unavailable for
screening or had recently undergone echocardiography
ruling out CTEPH. As citrate samples were lacking for 53
patients due to logistical reasons or patient refusal, our final
study population comprised 349 of the 402 (87 %) patients
that entered the CTEPH screening program (Fig. 2).
The study population consisted of 72 cases (20.6 %, i.e.
those with recurrent VTE) and 277 controls (79.4 %, i.e.
those with a first event at time of index PE). Median time
between index PE and the screening visit was 44 months
(2.5–97.5 percentiles 14–83 months). Patient characteristics
Fig. 2 Flow chart
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of cases and controls at time of screening are reported in
Table 1.
MP-TF activity
Median MP-TF activity was 32.2 fM Xa/min (2.5–97.5 per-
centile 0.0–181.7 fM Xa/min) for cases and 19.3 fM Xa/min
(2.5–97.5 percentile 0.00–192.5 fM Xa/min) for controls
(p = 0.12). Controls in whom the index event was unpro-
voked had a median MP-TF activity of 13.6 fM Xa/min
(2.5–97.5 percentile 0.0–230.2 fM Xa/min) compared with
21.8 fM Xa/min (2.5–97.5 percentile 0.0–163.2 fM Xa/min)
in controls in whom the index event was provoked by a
thromboembolic risk factor (p = 0.47). No evidence of an
association was observed between MP-TF activity and the
risk of recurrent VTE, comparing the different quintiles with
the reference group (i.e. those in the lowest quintile ofMP-TF
activity), with a non-significant crude OR of 1.3 (95 % CI
0.6–2.7) in the highest quintile of MP-TF activity (Table 2).
A regression analysis stratified for time (i.e. 0–2, 2–4, and
[4 years) between index PE and study visit showed no effect
of the duration of this time period on the association between
MP-TF activity and recurrent VTE (Table 2).
FVIII:C
Median FVIII:C was higher in cases than in controls, with
values of 1.8 IU/ml (2.5–97.5 percentile 0.9–3.4) versus
1.6 IU/ml (2.5–97.5 percentile 0.7–2.8), respectively
(p\ 0.001). Controls in whom the index event was
unprovoked had a higher FVIII:C than controls in whom
the index event was provoked by a risk factor for VTE,
with median values of 1.8 IU/ml (2.5–97.5 percentiles
0.9–2.9) and 1.6 IU/ml (2.5–97.5 percentiles 0.7–3.0),
respectively (p = 0.001). Compared with the reference
group (i.e. those in the lowest quintile of FVIII:C), patients
in the highest quintile were at increased risk of recurrent
VTE with an OR of 5.4 (95 % CI 1.9–15.1) (Table 3). The
risk of recurrence was slightly lower after adjustment for
age, gender and active malignancy at time of sampling,
with an OR of 4.2 (95 % CI 1.4–12.2). Patients with the
predefined threshold of FVIII:C[ 1.66 IU/ml were at
increased risk of recurrent VTE, with a crude OR of 1.6
(95 % CI 1.0–2.7). This increased risk was slightly adjus-
ted towards unity after correction for age, gender, active
malignancy at time of sampling (OR 1.4, 95 % CI 0.8–2.4).
In the regression analysis stratified for time between
index PE and study visit, no effect of time on the relative
risks of recurrent VTE comparing the different quintiles
with the reference group was observed. However, none of
the patients in the reference group in whom time between
index PE and study visit exceeded three years developed a
recurrent VTE. Therefore, relative risks of recurrent VTE
for the longest time stratum ([4 years between index PE
and the study visit) could not be computed.
Discussion
This study, in which we assessed the association between
MP-TF activity, FVIII:C and recurrent VTE, has two main
findings. First, there was no association between MP-TF
activity and the risk of VTE recurrences. Second, high
FVIII:C levels were associated with a 4-fold increased risk
of VTE recurrence. This finding was consistent throughout
the different strata of time between index PE and study
visit.
Until now, the role of MP-TF in VTE pathogenesis has
predominantly been studied in cancer patients, for whom
the risk of thromboembolic disease is markedly increased
[24, 25]. In patients with malignancy, MP-TF has been
proposed as a key link between cancer progression and
cancer-associated thrombosis, which are known to be
strongly connected [26]. However, studies assessing the
potential of MP-TF to predict VTE in cancer patients
yielded conflicting results. Although the majority of studies
on this topic reported high MP-TF levels or high MP-TF
activity to be associated with an increased risk of VTE [23,
27–29], two other studies could not confirm this association
[30, 31].
Studies evaluating the role of MP-TF in the patho-
physiology of VTE in the general (non-cancer) population
are scarce and so far no study specifically addressed its
association with recurrent VTE. Two previous studies
reported that MP-TF activity was not increased in patients
Table 1 Characteristics of included patients at time of registration
Cases Controls
N 72 277
Age (mean, SD) 58.8 (15.2) 53.5 (15.4)
Male gender 48 (66.7) 128 (46.2)
Provoked PEa 32 (44.4) 192 (69.3)
Body mass index (kg/m2, mean, SD) 29.0 (5.1) 28.1 (5.5)
Active malignancy 7 (9.7) 31 (11.2)
COPD 9 (12.5) 22 (7.9)
VKA use 51 (70.8) 47 (17.0)
History of stroke 8 (11.1) 37 (14.1)
Peripheral artery disease 0 (0.0) 5 (1.8)
Family history of VTE 28 (38.9) 91 (32.9)
Data are presented as n, % unless stated otherwise
SD standard deviation, PE pulmonary embolism, COPD chronic
obstructive pulmonary disease, VTE venous thromboembolism, IQR
interquartile range, VKA vitamin K-antagonist
a Index episode of PE
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with a first manifestation of acute VTE compared to control
patients [13, 32]. In contrast, Ye et al. did observe higher
monocyte-derived MP-TF levels and MP-TF activity in
patients with an acute episode of first or recurrent DVT
compared with healthy controls although this study com-
prised only 50 patients [14]. Moreover, compared with
healthy controls, the number of platelet and endothelial
derived MP-TF was only increased in those with recurrent
DVT, not in patients with a first DVT. The discrepancy
throughout the literature on the association between MP-
TF levels or activity and VTE might be a result of differ-
ences in methods and timing of blood sampling (i.e.
duration from the VTE event), patient setting (cancer-
patients or general VTE population), the absence of a
standardized assay to measure MP-TF, and the fact that
detection of MPs is cumbersome due to their small size
[33]. Based on the existing literature and the results of our
study, being the largest in this setting up to date, the
association between MP-TF activity and recurrent VTE in
the general VTE population appears to be weak or non-
existent.
It has well been established that factors associated with
a first episode of VTE may not necessarily be involved
with the development of recurrent events [34]. Whether
this scenario holds for FVIII:C is currently unclear.
Several studies conclusively found associations between
FVIII:C and a first manifestation of VTE [18, 35, 36],
whereas studies on FVIII:C and recurrent VTE have
shown conflicting results [15–20]. Four out of the six
studies in this setting demonstrated a positive association
between FVIII:C and the risk of recurrent VTE [16–19].
However, the large Leiden Thrombophilia study (LETS)
could not confirm this association [15]. Notably, this
study used a predefined cut-off of 1.66 IU/ml for the
definition of elevated FVIII:C, rather than studying per-
centiles of FVIII:C [35]. The Prevention of Recurrent
VTE(PREVENT) trial was also unable to find an associ-
ation between elevated FVIII:C and recurrent VTE,
although a non-significant trend towards a higher recur-
rence risk for patients with elevated FVIII:C was noted
(21 vs. 13 %, p = 0.18) [20]. In an attempt to provide
more clarity on this topic, we used the data of a large
sample of patients with acute PE. We did not observe an
association between recurrent VTE and increased FVIII:C
at the cut-off of 1.66 IU/ml, consistent with the LETS
study. However, when FVIII:C was divided in quintiles, a
4-fold increased risk of VTE recurrence was found for
patients with FVIII:C above the 80th percentile, thus
supporting the studies that found a positive association
between FVIII:C and the risk of recurrent VTE.
Table 2 Microparticle-tissue factor activity in cases and controls
Time to index PE Percentile MP-TF activity (fM Xa/min) Cases (N = 72) Controls (N = 277) ORa (95 % CI) ORb (95 % CI)
All patients 0–20 \0.9 15 55 Ref Ref
20–40 0.9–11.9 7 56 0.5 (0.2–1.2) 0.4 (0.2–1.2)
40–60 11.9–29.4 9 55 0.6 (0.2–1.5) 0.6 (0.2–1.5)
60–80 29.4–65.1 21 57 1.4 (0.6–2.9) 1.3 (0.6–2.9)
80–100 [65.1 20 54 1.3 (0.6–2.7) 1.3 (0.6–2.8)
0–2 years 0–20 \0.9 2 15 Ref Ref
20–40 0.9–11.9 2 14 0.9 (0.1–7.6) 1.1 (0.1–9.7)
40–60 11.9–29.4 2 14 0.9 (0.1–7.6) 1.1 (0.1–9.4)
60–80 29.4–65.1 4 15 1.7 (0.3–11.1) 1.5 (0.2–10.3)
80–100 [65.1 10 2 1.3 (0.2–10.9) 1.0 (0.1–9.1)
2–4 years 0–20 \0.9 8 24 Ref Ref
20–40 0.9–11.9 2 17 0.4 (0.1–1.9) 0.4 (0.1–2.1)
40–60 11.9–29.4 4 20 0.6 (0.2–2.3) 0.5 (0.1–2.0)
60–80 29.4–65.1 7 18 1.2 (0.4–3.8) 1.0 (0.3–3.9)
80–100 [65.1 9 21 1.1 (0.4–3.4) 0.9 (0.3–3.0)
[4 years 0–20 \0.9 5 18 Ref Ref
20–40 0.9–11.9 3 25 0.4 (0.1–2.0) 0.5 (0.1–2.3)
40–60 11.9–29.4 3 21 0.5 (0.1–2.5) 0.5 (0.1–2.7)
60–80 29.4–65.1 10 24 1.5 (0.4–5.2) 1.8 (0.5–6.6)
80–100 [65.1 9 23 1.4 (0.4–4.9) 1.8 (0.5–6.9)
Cases are patients with more than one episode of venous thromboembolism, whereas controls have experienced only one VTE episode
a Crude value
b Adjusted for age, gender, and malignancy at time of sampling
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This study has several strengths and limitations. The fact
that, in line with numerous previous reports, male gender
and unprovoked PE were identified as important determi-
nants for recurrent VTE, supports the representativeness of
our cohort. In addition most studies performed so far only
included patients with DVT, whereas the present study
focusses on patients with PE, and therefore, our study
provides new information to the literature. Furthermore, we
studied MP-TF and FVIII activity at least one year after PE
diagnosis, ruling out the initial effect of acute PE on the
test results. An important limitation of this study includes
the fact that a significant proportion of patients had died
before they could be included in the study, thereby
enhancing the risk of survival bias. Moreover, of the 588
patients alive at time of enrolment, 148 were unavailable
for objective testing on pulmonary hypertension and
therefore not included. We cannot exclude that is has
affected our study outcomes, in a worst-case scenario,
underestimating the association between MP-TF and
recurrent VTE. Second, as a consequence of its design, this
study is unable to assess whether MP-TF or FVIII activity
are predictive for recurrent VTE. Third, blood samples
were drawn at a various duration of follow-up after the
index event. Nonetheless, our regression analyses stratified
for time between index PE and study enrollment did not
demonstrate an effect of duration of this time period on the
association between MP-TF or FVIII:C and recurrent VTE.
Fourth, MP-TF activity was assessed once in every patient,
whereas MP-TF activity levels are known to fluctuate.
However, it is unlikely that this fluctuation would be dif-
ferent for cases and controls, thereby influencing our study
results on the association between MP-TF activity and
recurrent VTE. Yet, we recognize that further prospective
studies are needed to evaluate the association between MP-
TF activity in both the acute and chronic phase of estab-
lished thromboembolic disease and recurrent VTE.
To summarize, in our study population MP-TF does not
appear to play an important role in driving the risk for VTE
recurrences. Also considering the difficulty of this assay,
and its unavailability in most hospitals, implementation of
MP-TF in prognostic models for risk stratification does not
seem warranted. Additionally, our data provide supporting
evidence to consider elevated FVIII:C as a marker for a
hypercoagulable state and as a contributing factor for the
recurrence of VTE. Future prospective studies are neces-
sary to explore its potential as a tool for prognostication,
either by itself or in combination with other pro-thrombotic
markers.
Table 3 Factor VIII activity in cases and controls
Time to index PE Percentile FVIII:C (IU/ml) Cases (N = 72) Controls (N = 277) ORa (95 % CI) ORb (95 % CI)
All patients 0–20 0–1.20 5 57 Ref Ref
20–40 1.20–1.48 14 54 3.0 (1.0–8.8) 2.7 (0.9–8.1)
40–60 1.48–1.74 15 54 3.2 (1.1–9.3) 2.7 (0.9–8.1)
60–80 1.74–2.02 13 57 2.6 (0.9–7.8) 2.3 (0.8–7.1)
80–100 [2.02 25 53 5.4 (1.9–15.1) 4.2 (1.4–12.2)
0–2 years 0–20 0–1.20 1 9 Ref Ref
20–40 1.20–1.48 2 10 1.8 (0.1–23.4) 1.5 (0.1–22.4)
40–60 1.48–1.74 2 13 1.4 (0.1–17.7) 1.2 (0.1–16.8)
60–80 1.74–2.02 2 12 1.5 (0.1–19.2) 0.7 (0.0–12.5)
80–100 [2.02 3 13 2.1 (0.2–23.3) 1.4 (0.1–18.2)
2–4 years 0–20 0–1.20 4 22 Ref Ref
20–40 1.20–1.48 4 19 1.2 (0.2–5.3) 1.3 (0.3–6.1)
40–60 1.48–1.74 6 17 1.9 (0.5–8.0) 2.0 (0.4–8.8)
60–80 1.74–2.02 6 22 1.5 (0.4–6.1) 1.7 (0.4–7.5)
80–100 [2.02 11 22 2.8 (0.8–10.0) 2.7 (0.7–11.0)
[4 years 0–20 0–1.20 0 26 Ref Ref
20–40 1.20–1.48 8 25 Infinite Infinite
40–60 1.48–1.74 7 24 Infinite Infinite
60–80 1.74–2.02 5 23 Infinite Infinite
80–100 [2.02 11 18 Infinite Infinite
Cases are patients with more than one episode of venous thromboembolism, whereas controls have experienced only one VTE episode
a Crude value
b Adjusted for age, gender, and malignancy at time of sampling
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